Piotr Jankowski1, Dariusz A Kosior2,3, Paweł Sowa4, Karolina Szóstak-Janiak5, Paweł Kozieł6, Agnieszka Krzykwa3, Emilia Sawicka4, Maciej Haberka5, Małgorzata Setny3, Karol Kamiński4, Zbigniew Gąsior5, Aldona Kubica7, Dirk De Bacquer8, Guy De Backer8, Kornelia Kotseva9, David Wood9, Andrzej Pająk10, Danuta Czarnecka6. 1. I Department of Cardiology, Interventional Electrocardiology and Hypertension, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. piotrjankowski@interia.pl. 2. Mossakowski Medical Research Centre, Polish Academy of Science, Warsaw, Poland. 3. Department of Cardiology and Hypertension with the Electrophysiological Lab, Central Research Hospital the Ministry of The Interior and Administration, Warsaw, Poland. 4. Department of Population Medicine and Civilization Diseases Prevention, Medical University of Bialystok, Bialystok, Poland. 5. Department of Cardiology, Medical University of Silesia, Katowice, Poland. 6. I Department of Cardiology, Interventional Electrocardiology and Hypertension, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland. 7. Department of Health Promotion, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz , Poland. 8. Department of Public Health and Primary Care, Ghent University, Belgium. 9. Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London and National Institute of Preventive Cardiology, National University of Ireland-Galway, Galway, Ireland. 10. Department of Clinical Epidemiology and Population Studies, Institute of Public Health, Jagiellonian University Medical College, Krakow, Poland.
Abstract
BACKGROUND: The highest priority in preventive cardiology is given to patients with established coronary artery disease (CAD). The aim of the study was to assess the current implementation of the guidelines for secondary prevention in everyday clinical practice by evaluating control of the main risk factors and the cardioprotective medication prescription rates in patients following hospitalization for CAD. METHODS: Fourteen departments of cardiology participated in the study. Patients (aged ≤ 80 years) hospitalized due an acute coronary syndrome or for a myocardial revascularization procedure were recruited and interviewed 6-18 months after the hospitalization. RESULTS: Overall, 947 patients were examined 6-18 months after hospitalization. The proportion of patients with high blood pressure (≥ 140/90 mmHg) was 42%, with high low-density lipoprotein cholesterol (LDL-C ≥ 1.8 mmol/L) 62%, and with high fasting glucose (≥ 7.0 mmol/L) 22%, 17% of participants were smokers and 42% were obese. The proportion of patients taking an antiplatelet agent 6-18 months after hospitalization was 93%, beta-blocker 89%, angiotensin converting enzyme inhibitor or sartan 86%, and a lipid-lowering drug 90%. Only 2.3% patients had controlled all the five main risk factors well (non-smoking, blood pressure < 140/90 mmHg, LDL-C < 1.8 mmol/L and glucose < 7.0 mmol/L, body mass index < 25 kg/m2), while 17.9% had 1 out of 5, 40.9% had 2 out of 5, and 29% had 3 out of 5 risk factors uncontrolled. CONCLUSIONS: The documented multicenter survey provides evidence that there is considerable potential for further reductions of cardiovascular risk in CAD patients in Poland. A revision of the state funded cardiac prevention programs seems rational.
BACKGROUND: The highest priority in preventive cardiology is given to patients with established coronary artery disease (CAD). The aim of the study was to assess the current implementation of the guidelines for secondary prevention in everyday clinical practice by evaluating control of the main risk factors and the cardioprotective medication prescription rates in patients following hospitalization for CAD. METHODS: Fourteen departments of cardiology participated in the study. Patients (aged ≤ 80 years) hospitalized due an acute coronary syndrome or for a myocardial revascularization procedure were recruited and interviewed 6-18 months after the hospitalization. RESULTS: Overall, 947 patients were examined 6-18 months after hospitalization. The proportion of patients with high blood pressure (≥ 140/90 mmHg) was 42%, with high low-density lipoprotein cholesterol (LDL-C ≥ 1.8 mmol/L) 62%, and with high fasting glucose (≥ 7.0 mmol/L) 22%, 17% of participants were smokers and 42% were obese. The proportion of patients taking an antiplatelet agent 6-18 months after hospitalization was 93%, beta-blocker 89%, angiotensin converting enzyme inhibitor or sartan 86%, and a lipid-lowering drug 90%. Only 2.3% patients had controlled all the five main risk factors well (non-smoking, blood pressure < 140/90 mmHg, LDL-C < 1.8 mmol/L and glucose < 7.0 mmol/L, body mass index < 25 kg/m2), while 17.9% had 1 out of 5, 40.9% had 2 out of 5, and 29% had 3 out of 5 risk factors uncontrolled. CONCLUSIONS: The documented multicenter survey provides evidence that there is considerable potential for further reductions of cardiovascular risk in CAD patients in Poland. A revision of the state funded cardiac prevention programs seems rational.
Authors: Piotr Feusette; Marek Gierlotka; Iwona Krajewska-Redelbach; Aleksandra Kamińska-Kegel; Szymon Warzecha; Lidia Kalinowska; Joanna Szlachta; Katarzyna Kutkiewicz-Moroz; Jerzy Sacha; Agnieszka Wojdyła-Hordyńska; Robert Bryk; Piotr Jankowski; Mariusz Gąsior Journal: Kardiol Pol Date: 2019-02-26 Impact factor: 3.108
Authors: Maciej Banach; Piotr Jankowski; Jacek Jóźwiak; Barbara Cybulska; Adam Windak; Tomasz Guzik; Artur Mamcarz; Marlena Broncel; Tomasz Tomasik; Jacek Rysz; Agnieszka Jankowska-Zduńczyk; Piotr Hoffman; Agnieszka Mastalerz-Migas Journal: Arch Med Sci Date: 2016-12-19 Impact factor: 3.318
Authors: Kornelia Kotseva; Guy De Backer; Dirk De Bacquer; Lars Rydén; Arno Hoes; Diederick Grobbee; Aldo Maggioni; Pedro Marques-Vidal; Catriona Jennings; Ana Abreu; Carlos Aguiar; Jolita Badariene; Jan Bruthans; Almudena Castro Conde; Renata Cifkova; Jim Crowley; Kairat Davletov; Jaap Deckers; Delphine De Smedt; Johan De Sutter; Mirza Dilic; Marina Dolzhenko; Vilnis Dzerve; Andrejs Erglis; Zlatko Fras; Dan Gaita; Nina Gotcheva; Peter Heuschmann; Hosam Hasan-Ali; Piotr Jankowski; Nebojsa Lalic; Seppo Lehto; Dragan Lovic; Silvia Mancas; Linda Mellbin; Davor Milicic; Erkin Mirrakhimov; Rafael Oganov; Nana Pogosova; Zeljko Reiner; Stefan Stöerk; Lâle Tokgözoğlu; Costas Tsioufis; Dusko Vulic; David Wood Journal: Eur J Prev Cardiol Date: 2019-02-10 Impact factor: 7.804
Authors: Kornelia Kotseva; David Wood; Dirk De Bacquer; Guy De Backer; Lars Rydén; Catriona Jennings; Viveca Gyberg; Philippe Amouyel; Jan Bruthans; Almudena Castro Conde; Renata Cífková; Jaap W Deckers; Johan De Sutter; Mirza Dilic; Maryna Dolzhenko; Andrejs Erglis; Zlatko Fras; Dan Gaita; Nina Gotcheva; John Goudevenos; Peter Heuschmann; Aleksandras Laucevicius; Seppo Lehto; Dragan Lovic; Davor Miličić; David Moore; Evagoras Nicolaides; Raphael Oganov; Andrzej Pajak; Nana Pogosova; Zeljko Reiner; Martin Stagmo; Stefan Störk; Lale Tokgözoğlu; Dusko Vulic Journal: Eur J Prev Cardiol Date: 2015-02-16 Impact factor: 7.804
Authors: Aldona Kubica; Karolina Obońska; Michał Kasprzak; Beata Sztuba; Eliano Pio Navarese; Marek Koziński; Iwona Świątkiewicz; Magdalena Kieszkowska; Małgorzata Ostrowska; Grzegorz Grześk; Jacek Kubica Journal: Kardiol Pol Date: 2015-06-23 Impact factor: 3.108
Authors: Maria Radzimanowski; Christian Gallowitz; Jacqueline Müller-Nordhorn; Nina Rieckmann; Bernhard Tenckhoff Journal: Int J Cardiol Date: 2017-10-22 Impact factor: 4.164
Authors: Aldona Kubica; Michał Kasprzak; Karolina Obońska; Tomasz Fabiszak; Ewa Laskowska; Eliano Pio Navarese; Marek Koziński; Beata Sztuba; Iwona Świątkiewicz; Grzegorz Grześk; Jacek Kubica Journal: Pharmacology Date: 2015-01-15 Impact factor: 2.547
Authors: Kornelia Kotseva; Dirk De Bacquer; Catriona Jennings; Viveca Gyberg; Guy De Backer; Lars Rydén; Philippe Amouyel; Jan Bruthans; Renata Cifkova; Jaap W Deckers; Johan De Sutter; Zlatko Fraz; Ian Graham; Irena Keber; Seppo Lehto; David Moore; Andrzej Pajak; David Wood Journal: Glob Heart Date: 2016-03-16
Authors: Carola A Huber; Matthias R Meyer; Jan Steffel; Eva Blozik; Oliver Reich; Thomas Rosemann Journal: Clin Ther Date: 2018-12-24 Impact factor: 3.393
Authors: Siamala Sinnadurai; Pawel Sowa; Piotr Jankowski; Zbigniew Gasior; Dariusz A Kosior; Maciej Haberka; Danuta Czarnecka; Andrzej Pajak; Malgorzata Setny; Jacek Jamiolkowski; Emilia Sawicka-Śmiarowska; Karol Kaminski Journal: Int J Environ Res Public Health Date: 2022-05-25 Impact factor: 4.614
Authors: Paweł Kozieł; Piotr Jankowski; Sławomir Surowiec; Piotr Bogacki; Piotr Gomuła; Ewa Mirek-Bryniarska; Jadwiga Nessler; Piotr Podolec; Marek Rajzer; Danuta Czarnecka Journal: Postepy Kardiol Interwencyjnej Date: 2020-12-29 Impact factor: 1.426
Authors: Małgorzata Chlabicz; Jacek Jamiołkowski; Wojciech Łaguna; Paweł Sowa; Marlena Paniczko; Magda Łapińska; Małgorzata Szpakowicz; Natalia Drobek; Andrzej Raczkowski; Karol A Kamiński Journal: J Clin Med Date: 2021-04-09 Impact factor: 4.241
Authors: Małgorzata Chlabicz; Jacek Jamiołkowski; Wojciech Łaguna; Marlena Dubatówka; Paweł Sowa; Magda Łapińska; Anna Szpakowicz; Natalia Zieleniewska; Magdalena Zalewska; Andrzej Raczkowski; Karol A Kamiński Journal: J Clin Med Date: 2022-01-28 Impact factor: 4.241
Authors: Piotr Jankowski; Paweł Kozieł; Grzegorz Bilo; Jarosław Pinkas; Danuta Czarnecka; Kalina Kawecka-Jaszcz; Andrzej Pająk Journal: Int J Hypertens Date: 2022-08-05 Impact factor: 2.434
Authors: Natalia Drobek; Paweł Sowa; Piotr Jankowski; Maciej Haberka; Zbigniew Gąsior; Dariusz Kosior; Danuta Czarnecka; Andrzej Pająk; Karolina Szostak-Janiak; Agnieszka Krzykwa; Małgorzata Setny; Paweł Kozieł; Marlena Paniczko; Jacek Jamiołkowski; Irina Kowalska; Karol Kamiński Journal: J Clin Med Date: 2021-05-05 Impact factor: 4.241
Authors: Aleksandra Gąsecka; Bartholomew Rzepa; Aleksandra Skwarek; Agata Ćwiek; Kinga Pluta; Łukasz Szarpak; Miłosz J Jaguszewski; Tomasz Mazurek; Janusz Kochman; Grzegorz Opolski; Krzysztof J Filipiak; Krzysztof Gąsecki Journal: Zdr Varst Date: 2021-12-27